Home › Companies › AUTL

Autolus Therapeutics

AUTL Rare disease Lead: Approved 1 Biotech Distilled article ↓

Hematology Immunology Neurology Oncology Renal Cell

Most recent annual filing: 2026-03-27

Pipeline (12 active programs)

AUCATZYL

obecabtagene autoleucel · obe-cel · AUTO1

Cell Target: CD19

AUTO1/22

Cell Target: CD19, CD22

Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia Phase 1 UCL

AUTO8

Cell Target: BCMA, CD19

Biotech Distilled coverage (1)

2026-05-23 Autolus Therapeutics (AUTL) — Scientific Deep Dive for Obe-cel and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.